Trials / Completed
CompletedNCT00207168
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
A Randomized, Multi-center, Open Label Study in Well Controlled Treatment-experienced HIV- Infected Patients to Assess Compliance With a Once-daily Regimen
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess compliance of once daily dosing to assess their benefits in terms of potency and safety as well as their impact on adherence and quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Compliance |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2005-09-21
- Last updated
- 2011-04-22
Source: ClinicalTrials.gov record NCT00207168. Inclusion in this directory is not an endorsement.